A Study of AAV2-GDNF in Adults with Moderate Parkinsons Disease (REGENERATE-PD)

Recruiting
75 years or below
All
Phase 2
1 Location

Brief description of study

The study is designed to evaluate the efficacy and safety of intraputaminal delivery of AAV2-GDNF gene therapy in subjects with moderate Parkinson's disease and demonstrate proof-of-concept. Subjects will be randomized to 1 of 2 treatment arms, AAV2-GDNF surgery or control surgery and will undergo screening, two baseline visits, perioperative procedures, and double-blind follow-up. Procedures include biological fluid sampling; MRI, CT, PET imaging, clinical assessments; and activity monitoring.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 75 years or below
  • Gender: All

TBD

Updated on 02 Jul 2025. Study ID: 24-0324

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Please provide your preferred way of contact
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center